Last week in GLP1 (2025/10/13)

GLP1.Guide Staff

13 Oct 2025 — 1 min read

We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed:

🔎 GLP1 interfering with medical imaging?

💚 More research on GLP1’s benefits for stopping substance & alcohol Abuse

📑 Ketones + GLP1s prevent muscle loss (in mice)

🚨 Semaglutide Withdrawal and it’s effects on Type 1 Diabetes

🏆 European association picks GLP1s as first line obesity treatments

Want to get the links and read more?
Check us out on Substack 👇

The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:

Read the rest on Substack

Last week in GLP1 (2025/10/06)

We’ve gathered some key stories from the GLP1 ecosystem in the last week you might have missed: 💼 Costco is now selling heavily discounted GLP1s 🦘 Buzz in Australia around GLP1s as a public benefit 💊 Excitement is growing around oral GLP1s 🏫 Harvard doctor doubles down on benefits of GLP1 for inflammation

Last week in GLP1 (2025/09/22)

Here’s what happened last week in the GLP1 ecosystem: 📊 Study: Wegovy pill shows 16.6% weight loss 📢 Eli Lilly says Orforglipron is even better than the Wegovy pill 📺 GLP1s in patch form? Not yet 📑 GLP1s could reduce all-cause mortality by up to 6% by 2045 ❓Bariatric surgery more effective

A new study on GLP1s eye risk

One of the biggest emerging risks of using GLP1s has been the link between GLP1s and vision loss — whether via NAION or macular degeneration. We’ve covered this before: The link between Semaglutide & vision loss (NAION)How deep is the link between GLP1s and possible vision loss? We examine

Last week in GLP1 (2025/09/15)

Here’s what happened last week in the GLP1 ecosystem: 🧑‍⚖️ Lawsuits over the negative side effects of GLP1s 🌐 The WHO is building a guideline for GLP1 use and requesting comments 🎭 Celebrity endorsements continue: Andy Cohen reveals use of GLP1s for weight management 🚨 GLP1 is now being used in SMS scams